Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.
about
Management of hemolytic-uremic syndrome in childrenHUS and TTP in ChildrenHemolytic uremic syndrome: toxins, vessels, and inflammationRenal and neurological involvement in typical Shiga toxin-associated HUS.Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects.Fatal hemolytic uremic syndrome associated with day care surgery and anaesthesia: a case report.New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndromeUltrasound findings in EHEC-associated hemolytic-uremic syndrome and their clinical relevance.Role of bacteriophages in STEC infections: new implications for the design of prophylactic and treatment approachesPromoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model.A hemolytic-uremic syndrome-associated strain O113:H21 Shiga toxin-producing Escherichia coli specifically expresses a transcriptional module containing dicA and is related to gene network dysregulation in Caco-2 cells.Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice.Peptides derived from phage display libraries as potential neutralizers of Shiga toxin-induced cytotoxicity in vitro and in vivo
P2860
Q27002576-9AF755A7-C79F-4688-BDD7-FC79BE4FA900Q27026538-A6CBF271-5E64-4C5F-B548-4080E16B2089Q28083347-1FCC08B4-C888-450E-BB2E-45F9BB6EBE7AQ33403361-A4E3D313-70CA-4618-963C-BC085D920C6FQ33404888-727503EF-674F-4B58-A6F5-8CDD45BFBA63Q33408687-BDEEC8BB-597B-4F9B-A08B-CAEE60732C42Q33409878-FC9EA1E3-98AD-4F7B-923F-89B3D82E2A3DQ33429127-B21AD12D-04A8-4795-A5AA-0E23717EB704Q34885883-932E317B-2DF0-41EC-A530-39A450FE5340Q37218835-9D44EA7E-2790-4985-A442-E42AD1025B15Q37672981-4DCC81C3-17F5-47BC-AA1B-B04C39E0B98FQ47108133-385D7063-BC79-4F78-9C11-2AE3D1A6E99BQ47321222-808A3290-8070-4A9E-8D1D-79D6E859E2F0Q55324511-D7C11C4F-5328-4E89-94BD-95A0072B4D8DQ56891315-94292E09-F9B0-45B7-9DBB-BB1025904EAC
P2860
Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@ast
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@en
type
label
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@ast
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@en
prefLabel
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@ast
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@en
P2860
P1476
Shiga toxin-associated hemolyt ...... pathogenesis and therapeutics.
@en
P2093
Philip A Marsden
Tania N Petruzziello-Pellegrini
P2860
P304
P356
10.1097/MNH.0B013E328354A62E
P577
2012-07-01T00:00:00Z